Locally advanced
High-risk or very high-risk PCa
Young patients with high-grade PCa
Stage IIIB–IVA PCa
Recurrent PCa follow-up
Domestic and international referrals
China Medical University Hospital's Urology Department, led by Director Chi-Ping Huang, has performed Da Vinci radical prostatectomy since February 2012, accumulating over 2,566 cases by May 2024 — among Taiwan's top 5 in Da Vinci surgery volume. This study focuses on locally advanced prostate cancer (Stages IIIB, IIIC, IVA), using the 4th-generation Xi system to perform "radical" Da Vinci prostatectomy with the innovative "Early Salvage Therapy" approach replacing indiscriminate post-op adjuvant therapy. The study enrolled 79 patients with average follow-up exceeding 60 months. Results: 48% of patients avoided post-op adjuvant therapy; 72% in lymph-node-negative patients. Three-year BCR-free rate: 72.1% (international 63.3%); 5-year BCR-free rate: 57.0% (international 51.0%); overall survival: 98.7%; Stage III survival: 87.80%; Stage IV survival: 64.16% (national 55.35%). Median blood loss 50ml (intl 200ml), post-op complications only 3.8% (intl 12.7%), median lymph node retrieval 24 (intl 16).
Early Salvage Therapy: Taiwan pioneer
4th-gen Xi Da Vinci safest system
Multidisciplinary tumor board decision
Aggressive radical surgery for advanced cases
Average follow-up >60 months
Active option for young high-grade patients
Cumulative 2,566 Da Vinci surgeries
2023: 318 Da Vinci surgeries
Avg monthly surgical volume: 26
79 patients enrolled in study
6.1% national Da Vinci surgery share
High/very high-risk stages: 72.1%
3-yr BCR-free rate: 72.1% (intl 63.3%)
5-yr BCR-free rate: 57.0% (intl 51.0%)
Overall survival: 98.7%
Stage III survival: 87.80%
Stage IV survival: 64.16% (national 55.35%)
48% avoid post-op adjuvant therapy
Median blood loss: 50ml (intl 200ml)
Post-op complications: 3.8% (intl 12.7%)
Post-op transfusion: 0% (intl 4.3%)
Re-operation rate: 0%
Patient loss-to-follow-up rate: 0%
Median lymph node retrieval: 24 (intl 16)
Dedicated case manager full-process tracking
0% loss-to-follow-up indicates high trust
Avoiding adjuvant therapy reduces side effects
Reduces patient psychological stress
Win-win-win model saves medical expenses
High mid-long term follow-up compliance
2022 SCI publication in Medicina
2022 Cross-Strait Symposium Taiwan representative
2023 hosted international urological robotic symposium
Invited Dr. Abaza, Dr. Rha to operate in Taiwan
2024 Taiwan Urological Society Annual Conference
Data surpasses top EAU teams
Creates clinical, NHI, patient triple-win
Reduces adjuvant therapy proportion
Saves NHI resources
Provides curative option for advanced cases
Pioneers domestic treatment paradigm
